Increased PAD prevalence in prolactinomas and somatoprolactinomas has been associated with increased mRNA targeting of oncogenes HMGA, Insulin-like Growth Factor 1 (IGF-1), and Neuroblastoma MYC Oncogene (N-MYC) by miRNAs, which may yield insight into the etiology of the affected tumor subtypes (75). Here, IGF1 is linked to peripheral arterial disease.